Clinical trials: Empagliflozin
Type 2 Diabetes
Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets
This study is a post-marketing, multicenter, prospective, observational study designed to evaluate the efficacy and safety of Proline Plus Empagliflozin Tablets in the real-world clinical treatment of type 2 diabetes mellitus.
- Trial name
- NCT07023172
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Heart Failure With Reduced Ejection Fraction
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable…
- Trial name
- Empire HF (NCT03198585)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Denmark
- Volunteers
- 190 people
- Sponsor
- Morten Schou
Diabetes Mellitus, Type 2
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to identify and evaluate the event rate of the composite endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for participants with Type 2 Diabetes mellitus (T2DM) and…
- Trial name
- NCT03249506
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 25,358 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Kidney Diseases, Pediatric Kidney Disease
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD).
- Trial name
- SGLT2I-IN-KIDS (NCT06430684)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Type 2 Diabetes (T2DM)
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people.
- Trial name
- Beta (NCT07325435)
- Testing
- SGLT-2 inhibitor, GLP1-RA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MaryAnn Banerji
Type1 Diabetes Mellitus
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting
The most advanced configurations of the Artificial Pancreas (AP) have not yet been demonstrated to sufficiently maximize time in target glycemia.
- Trial name
- CLASS17 (NCT03979352)
- Testing
- empagliflozin, artificial pancreas
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Type II Diabetes
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus
- Trial name
- PIEMONTE (NCT05028140)
- Testing
- PIEMONTE, EMPAGLIFLOZIN, PIOGLITAZONE
- Where
- Brazil
- Volunteers
- 480 people
- Sponsor
- EMS
Major Depressive Disorder
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
The primary purpose of this study is to determine whether empagliflozin, a medication in a class known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, may reduce symptoms of depression.
- Trial name
- NCT05757791
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Heart Failure, Obesity
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
The aim of this trial is to assess the effect of Empagliflozin on cardiac mass, volumes, cardiac biomarkers, metabolism, daily activity level, health-related quality of life in patients in elderly and obese patients with…
- Trial name
- NCT05084235
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Denmark
- Volunteers
- 191 people
- Sponsor
- Jacob Moller
Non Alcoholic Steatohepatitis
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate the possible beneficial effect of empagliflozin versus pioglitazone on non-diabetic patients with non-alcoholic steatohepatitis (NASH). This study will be a randomized, comparative parallel study.
- Trial name
- NCT05605158
- Testing
- Pioglitazone 30mg, Empagliflozin 10 MG
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Aortic Valve Stenosis
EMPagliflozin After Aortic Valve Replacement
The study is a randomized, placebo-controlled, and double-blinded trial in patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR).
- Trial name
- EMPAVR (NCT06171802)
- Testing
- Empagliflozin
- Where
- Denmark
- Volunteers
- 206 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Failure
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%.
- Trial name
- NCT06935370
- Testing
- vicadrostat, empagliflozin
- Where
- 594 sites in United States, Argentina and 27 more
- Volunteers
- 4,200 people
- Sponsor
- Boehringer Ingelheim
Obesity
Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity
The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group). .
- Trial name
- NCT04043702
- Testing
- The intervention being studied
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ministry of Health and Population, Egypt
Heart Failure With Reduced Ejection Fraction
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
The study is a short to mid-term randomized single-blind placebo controlled study that aimed to detect the effects of empagliflozin (a sodium-glucose cotransporter-2 inhibitor) compared to placebo on LV end-diastolic and…
- Trial name
- HFrEF (NCT06632561)
- Testing
- Empagliflozin 10 mg
- Where
- Egypt
- Volunteers
- 74 people
- Sponsor
- Ashraf Wasfy Beshay Aziz
Healthy
Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
To investigate the relative bioavailability of BI 10773 following coadministration with 600 mg gemfibrozil bid dosed to steady-state in comparison to BI 10773 when given alone.
- Trial name
- NCT01301742
- Testing
- BI 10773, Gemfibrozil
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of two strength of empagliflozin and metformin (Part I) under fasted and under fed conditions and bioequivalence of empagliflozin/metformin…
- Trial name
- NCT01811953
- Testing
- Empagliflozin, Metformin, Empagliflozin/Metformin
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR…
- Trial name
- NCT02106923
- Testing
- 1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
DW6014
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6014 and each component in healthy adult volunteers in fed condition.
- Trial name
- NCT05823883
- Testing
- DW6014
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Kidney Transplantation, Metabolic Disorder
Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)
Advances in patient selection, organ procurement and preservation, surgical technique, immunosuppression, and infection prevention have conferred significant decrease in rejection, infection, and subsequently improve…
- Conditions
- Kidney Transplantation, Metabolic Disorder, Metformin, Empagliflozin
- Trial name
- NCT05013112
- Testing
- SGLT2 inhibitor, Metformin
- Where
- China
- Volunteers
- 105 people
- Sponsor
- West China Hospital
Metabolic Syndrome, Type 2 Diabetes Mellitus
Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans
This study is designed to investigate whether the sodium-glucose co-transporter-2 (SGLT-2) inhibitor Empagliflozin reduces sympathetic nervous system (SNS) activity in humans.
- Conditions
- Metabolic Syndrome, Type 2 Diabetes Mellitus, Obesity
- Trial name
- EMPA-SNS (NCT03912909)
- Testing
- Empagliflozin Oral Tablet [Jardiance]
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Royal Perth Hospital